Sustainable thymol-based formulations with amoxicillin and Melaleuca alternifolia essential oil
Abstract
Antimicrobial resistance (AMR) against antibiotics is caused by the evolution of pathogens to endure antibiotics, rendering once powerful treatments now useless. Amoxicillin (A), a well-known antibiotic is subjected to AMR and could be more effective in combination with plant-based extracts. Tea Tree essential oil (T) and thymol (t) are known antimicrobial agents but are hampered by their lipophilicity, volatility, oxidative degradation and skin irritation. These disadvantages can be mitigated by combinations to achieve better drug delivery outcomes. Thymol, a monoterpenoid has remarkable antimicrobial activities, but several pathogens are resistant to it. T is utilized since centuries against ailments but requires nanoencapsulation due to drug-delivery problems. Formulations consisting of T, thymol, and amoxicillin (A) were investigated as possible alternatives against AMR. The best combination with highest antimicrobial properties was identified as Tt2A2, consisting of T, thymol, and A at 1:2:2 proportions, respectively. Small-sized particles of Tt2A2 were subjected to ultraviolet-visible (UV-Vis) spectrometry, Fourier transform infrared (FTIR) spectroscopy, x-ray diffraction (XRD), scanning electron microscopy (SEM), and energy dispersive x-ray (EDX) spectroscopy analysis. Tt2A2 was tested against ten microbial reference strains on discs, surgical sutures, cotton gauze bandages, surgical face masks, and KN95 masks by agar-disc diffusion methods. The formulations of Tt2A2…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.